<DOC>
	<DOCNO>NCT02720926</DOCNO>
	<brief_summary>Standard `` 3+3 '' dose escalation design TKI258/XELOX advance gastric/gastro-oesophageal colorectal cancer .</brief_summary>
	<brief_title>Study TKI 258 Combination With Xeloda Oxaliplatin Advanced Colorectal Gastric Cancer</brief_title>
	<detailed_description>This `` 3+3 '' dose escalation design 4 pre-defined TKI258 dose level ( 200mg , 300mg , 400mg 500mg daily 5 day 2 day schedule ) combination fix standard dose XELOX ( Capecitabine Oxaliplatin ) establish recommend phase 2 dose .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Patients must histologically confirm gastric , gastrooesophageal colorectal adenocarcinoma . 2 . The gastric gastrooesophageal cancer must locally advance unresectable metastatic . Colorectal cancer must metastatic subsequent resection metastatic disease assess feasible . 3 . Age &gt; 18 year . 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; 2 ( Karnofsky &gt; 60 % , see Appendix A ) . 5 . Life expectancy great 3 month 6 . Patients must normal organ marrow function define : leukocyte &gt; 3,000/mcL absolute neutrophil count &gt; 1,500/microliter ( mcL ) TKI258/XELOX phase 1 protocol version 3.3 Dated 30 November 2011 1 3 platelet &gt; 100,000/mcL total bilirubin &lt; = 1.5 x upper limit normal ( ULN ) aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) &lt; 2.5 X institutional upper limit normal creatinine within normal institutional limit OR creatinine clearance &gt; 55 mL/min patient creatinine level institutional normal . 7 . The effect TKI258 XELOX develop human fetus unknown . For reason , woman childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Should woman become pregnant suspect pregnant participating study , inform treat physician immediately . 8 . Baseline leave ventricular ejection fraction ( LVEF ) &gt; = 50 % 9 . Ability understand willingness sign write informed consent document . 1 . Patients consider `` currently active '' malignancy TKI258/XELOX phase 1 protocol version 3.3 Dated 30 November 2011 1 4 complete therapy consider less 30 % risk relapse . 2 . Pregnant woman exclude study potential teratogenic abortifacient effect . Because unknown potential risk adverse event nurse infant secondary treatment mother TKI258 XELOX , breastfeed discontinue mother treated TKI258 XELOX . 3 . Patients prior history transient ischemia attack cerebrovascular disease prior history ischemia heart disease myocardium infarction 2 risk factor : ever smoker &gt; 30 pack per year exposure medication diabetes mellitus hypertension hyperlipidemia . 4 . In addition Beginning dose expansion cohort , follow exclusion criterion apply : Patients agreeable collection tumor tissue correlative study Patients tumor tissue correlative study safely obtain .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>